Answers are grounded in this paper and cite their sources.
Randomized trials show TAS-102 improves survival in metastatic colorectal cancer, suggesting a promising treatment option.
TAS-102 is a new oral anti-tumor drug, composed of a thymidine-based nucleoside analog (trifluridine: FTD) and a thymidine phosphorylase inhibitor (tipiracil hydrochloride: TPI). TAS-102 has been shown to significantly improve overall survival and progression-free survival in patients with refractory metastatic colorectal cancer (mCRC) in placebo-controlled randomized phase II and III trials. The current review summarizes mechanisms of action, pharmacokinetics/dynamics and preclinical and clinical data of TAS-102 in colorectal cancer. TAS-102 is a new salvage-line treatment option for patients with mCRC. TAS-102 is well tolerated and has great potential in future clinical drug combination therapies.
No takes yet. Share an insight, caveat, or question.
Miyamoto et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: